These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
821 related articles for article (PubMed ID: 25341154)
1. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone. Kim JH; Kim PN; Won HJ; Shin YM AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154 [TBL] [Abstract][Full Text] [Related]
2. Radiofrequency ablation for viable hepatocellular carcinoma around retained iodized oil after transcatheter arterial chemoembolization: usefulness of biplane fluoroscopy plus ultrasound guidance. Min JH; Lee MW; Rhim H; Choi D; Kim YS; Kim YJ; Cha DI; Lim HK Korean J Radiol; 2012; 13(6):784-94. PubMed ID: 23118578 [TBL] [Abstract][Full Text] [Related]
3. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. Lee DH; Lee JM; Kim PN; Jang YJ; Kang TW; Rhim H; Seo JW; Lee YJ Eur Radiol; 2019 Sep; 29(9):5052-5062. PubMed ID: 30770968 [TBL] [Abstract][Full Text] [Related]
4. Computed tomographic-guided radiofrequency ablation of recurrent or residual hepatocellular carcinomas around retained iodized oil after transarterial chemoembolization. Koh YH; Choi JI; Kim HB; Kim MJ Korean J Radiol; 2013; 14(5):733-42. PubMed ID: 24043966 [TBL] [Abstract][Full Text] [Related]
5. Iodized Oil Transarterial Chemoembolization and Radiofrequency Ablation for Small Periportal Hepatocellular Carcinoma: Comparison with Nonperiportal Hepatocellular Carcinoma. Lee SY; Hyun D; Cho SK; Shin SW; Jung SH; Chi SA Cardiovasc Intervent Radiol; 2018 Jan; 41(1):120-129. PubMed ID: 28924943 [TBL] [Abstract][Full Text] [Related]
6. Pattern and chronological change of iodized oil retention in radiofrequency ablation-induced vascular injury area: differentiation from iodized oil retention in recurrent hepatocellular carcinoma on computed tomography. Lee JY; Kim YS; Rhim H; Lim HK; Choi D; Lee WJ J Comput Assist Tomogr; 2010; 34(3):354-61. PubMed ID: 20498535 [TBL] [Abstract][Full Text] [Related]
7. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. El-Kady NM; Esmat G; Mahmoud EH; Darweesh SK; Mahmoud SH; Elagawy WA Eur J Gastroenterol Hepatol; 2013 May; 25(5):628-33. PubMed ID: 23325283 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Kim JW; Kim JH; Won HJ; Shin YM; Yoon HK; Sung KB; Kim PN Eur J Radiol; 2012 Mar; 81(3):e189-93. PubMed ID: 21353417 [TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Kim JW; Kim JH; Sung KB; Ko HK; Shin JH; Kim PN; Choi HK; Ko GY; Yoon HK; Chun SY; Gwon DI Am J Gastroenterol; 2014 Aug; 109(8):1234-40. PubMed ID: 24935276 [TBL] [Abstract][Full Text] [Related]
10. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation. Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215 [TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study. Haochen W; Jian W; Li S; Tianshi L; Xiaoqiang T; Yinghua Z J Int Med Res; 2018 Jul; 46(7):2650-2657. PubMed ID: 29683022 [TBL] [Abstract][Full Text] [Related]
12. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes. Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691 [TBL] [Abstract][Full Text] [Related]
13. [Transarterial chemoembolization plus computed tomography-guided percutaneous radiofrequency ablation for small hepatocellular carcinoma in special locations]. Guo YJ; Huang WS; Zhou B; Chen JW; Cai MY; Qian JS; Huang MS; Shan H; Zhu KS Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(33):2627-30. PubMed ID: 24360041 [TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection. Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A). Lee H; Yoon CJ; Seong NJ; Jeong SH; Kim JW Korean J Radiol; 2018; 19(6):1130-1139. PubMed ID: 30386144 [TBL] [Abstract][Full Text] [Related]
17. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512 [TBL] [Abstract][Full Text] [Related]
18. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188 [TBL] [Abstract][Full Text] [Related]
19. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma in the Caudate Lobe. Lee BC; Liu KL; Wu CH; Huang KW; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH; Liang PC Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1699-1707. PubMed ID: 29946941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]